{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=exemestane&page=3", "query": { "intervention": "exemestane", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=exemestane&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=exemestane&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T21:02:48.231Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06105632", "title": "A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "PF-07220060 CDK4 inhibitor", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2024-01-09", "completion_date": "2028-01-21", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 9, "location_summary": "Irvine, California • Los Angeles, California • Newport Beach, California + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06105632" }, { "nct_id": "NCT02236572", "title": "Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2014-11-29", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-02-01", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236572" }, { "nct_id": "NCT01381874", "title": "A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic ER+ Her2- Breast Cancer", "Postmenopausal" ], "interventions": [ { "name": "Exemestane", "type": "DRUG" }, { "name": "Abiraterone acetate + Prednisone/ Prednisolone + Exemestane", "type": "DRUG" }, { "name": "Abiraterone acetate + Prednisone or Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 297, "start_date": "2011-08-24", "completion_date": "2018-08-08", "has_results": true, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 24, "location_summary": "Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381874" }, { "nct_id": "NCT05607004", "title": "(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Invasive Breast Cancer", "Estrogen-receptor-positive Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "(Z)-endoxifen", "type": "DRUG" }, { "name": "goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atossa Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2023-02-14", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05607004" }, { "nct_id": "NCT01331434", "title": "Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roxane Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 47, "start_date": "2004-10", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 1, "location_summary": "Springfield, Missouri", "locations": [ { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331434" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT06001762", "title": "TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Early-stage Breast Cancer", "High Risk Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 90, "start_date": "2023-10-05", "completion_date": "2027-01-01", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 12, "location_summary": "Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Brewer", "state": "Maine" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001762" }, { "nct_id": "NCT03691493", "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-02-08", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691493" }, { "nct_id": "NCT07174336", "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY4064809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-12-22", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 129, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174336" }, { "nct_id": "NCT04852887", "title": "De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Breast Cancer" ], "interventions": [ { "name": "Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)", "type": "OTHER" }, { "name": "Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "50 Years to 70 Years" }, "enrollment_count": 1670, "start_date": "2021-06-23", "completion_date": "2041-07", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-16T21:02:48.231Z", "location_count": 812, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04852887" } ] }